Please login to the form below

Not currently logged in
Email:
Password:

Janssen boosts vaccines pipeline with GlycoVaxyn deal

Research will focus on targeting multiple bacterial pathogens

Janssen has agreed a deal with Swiss vaccines specialist GlycoVaxyn to research and develop a vaccine for multiple bacterial pathogens.

Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead commercialisation of any product that gains approval.

The partners' research efforts will make use of GlycoVaxyn's bio-conjugation technology, which is designed to support the development of polyvalent conjugate vaccines – a form of vaccine that can be used to protect against multiple targets.

GlycoVaxyn's co-founder and chief scientific officer Michael Wacker said the technology “should make the development and commercialisation of these vaccines more feasible and reliable”.

Financial details of the deal were not disclosed, although GlycoVaxyn will receive an upfront and milestone payments, plus reimbursement of R&D expenses and royalties on future sales.

The announcement comes just weeks after GlycoVaxyn signed another big pharma deal, tying up with GSK to collaborate on the development of anti-bacterial conjugate vaccines.

As with the Janssen deal, financial terms were not disclosed, nor the specific type of infection to be targeted.

The two deals in quick succession demonstrate a wider faith in GlycoVaxyn's bio-conjugate vaccine platform, and the company's CEO Philippe Dro welcomed the latest agreement.

He said: “This collaboration is a further confirmation of the position GlycoVaxyn is about to occupy in the vaccine development space.

“The whole team is dedicated to establish GlycoVaxyn's technology as a powerful platform able to generate innovative vaccine candidates.”

8th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics